X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Cipla with Cadila Healthcare - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CIPLA vs CADILA HEALTHCARE - Comparison Results

CIPLA    Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

CADILA HEALTHCARE 
   Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CIPLA CADILA HEALTHCARE CIPLA/
CADILA HEALTHCARE
 
P/E (TTM) x 45.4 33.8 134.1% View Chart
P/BV x 4.0 6.3 63.0% View Chart
Dividend Yield % 0.3 0.7 43.3%  

Financials

 CIPLA   CADILA HEALTHCARE
EQUITY SHARE DATA
    CIPLA
Mar-17
CADILA HEALTHCARE
Mar-17
CIPLA/
CADILA HEALTHCARE
5-Yr Chart
Click to enlarge
High Rs622460 135.2%   
Low Rs458305 150.3%   
Sales per share (Unadj.) Rs181.992.1 197.4%  
Earnings per share (Unadj.) Rs12.914.8 86.9%  
Cash flow per share (Unadj.) Rs29.318.5 158.6%  
Dividends per share (Unadj.) Rs2.003.20 62.5%  
Dividend yield (eoy) %0.40.8 44.3%  
Book value per share (Unadj.) Rs155.768.0 229.0%  
Shares outstanding (eoy) m804.511,023.74 78.6%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x3.04.2 71.5%   
Avg P/E ratio x42.025.8 162.6%  
P/CF ratio (eoy) x18.420.7 89.0%  
Price / Book Value ratio x3.55.6 61.7%  
Dividend payout %15.521.6 72.0%   
Avg Mkt Cap Rs m434,516391,581 111.0%   
No. of employees `00023.016.9 136.7%   
Total wages/salary Rs m26,33815,002 175.6%   
Avg. sales/employee Rs Th6,349.15,594.5 113.5%   
Avg. wages/employee Rs Th1,143.0890.1 128.4%   
Avg. net profit/employee Rs Th449.3899.9 49.9%   
INCOME DATA
Net Sales Rs m146,30294,295 155.2%  
Other income Rs m2,2871,286 177.8%   
Total revenues Rs m148,58995,581 155.5%   
Gross profit Rs m24,75819,036 130.1%  
Depreciation Rs m13,2293,750 352.8%   
Interest Rs m1,594450 354.2%   
Profit before tax Rs m12,22216,122 75.8%   
Minority Interest Rs m0338 0.0%   
Prior Period Items Rs m-700-   
Extraordinary Inc (Exp) Rs m0-3 0.0%   
Tax Rs m1,7981,289 139.5%   
Profit after tax Rs m10,35415,168 68.3%  
Gross profit margin %16.920.2 83.8%  
Effective tax rate %14.78.0 184.0%   
Net profit margin %7.116.1 44.0%  
BALANCE SHEET DATA
Current assets Rs m87,37060,223 145.1%   
Current liabilities Rs m33,08153,058 62.3%   
Net working cap to sales %37.17.6 488.4%  
Current ratio x2.61.1 232.7%  
Inventory Days Days8770 124.5%  
Debtors Days Days6288 70.7%  
Net fixed assets Rs m111,56772,984 152.9%   
Share capital Rs m1,6091,024 157.1%   
"Free" reserves Rs m123,64568,576 180.3%   
Net worth Rs m125,25469,600 180.0%   
Long term debt Rs m36,45424,684 147.7%   
Total assets Rs m209,532152,207 137.7%  
Interest coverage x8.736.8 23.5%   
Debt to equity ratio x0.30.4 82.1%  
Sales to assets ratio x0.70.6 112.7%   
Return on assets %5.710.3 55.6%  
Return on equity %8.321.8 37.9%  
Return on capital %8.517.9 47.4%  
Exports to sales %34.20-   
Imports to sales %8.30-   
Exports (fob) Rs m50,050NA-   
Imports (cif) Rs m12,203NA-   
Fx inflow Rs m51,06621,280 240.0%   
Fx outflow Rs m17,67810,874 162.6%   
Net fx Rs m33,38810,406 320.9%   
CASH FLOW
From Operations Rs m23,82413,495 176.5%  
From Investments Rs m-13,127-29,103 45.1%  
From Financial Activity Rs m-13,23923,158 -57.2%  
Net Cashflow Rs m-2,4787,556 -32.8%  

Share Holding

Indian Promoters % 16.0 74.8 21.4%  
Foreign collaborators % 20.8 0.0 -  
Indian inst/Mut Fund % 12.2 8.3 147.0%  
FIIs % 23.7 5.9 401.7%  
ADR/GDR % 1.1 0.0 -  
Free float % 26.2 11.0 238.2%  
Shareholders   161,166 44,069 365.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CIPLA With:   NOVARTIS  TORRENT PHARMA  FRESENIUS KABI ONCO.  WYETH LTD  ABBOTT INDIA  

Compare CIPLA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Breaches 36,000 Mark; ONGC Nears 52-Week High(Closing)

The NSE Nifty on Tuesday sailed past the 11,000 mark, while the BSE Sensex breached the 36,000 level for the first time after an IMF report showed India was set to regain.

Related Views on News

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Cipla: Extraordinary Income Boosts Net Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

Proceeds from the sale of the South African animal business bolstered Cipla's net profits for the quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

More Views on News

Most Popular

Mutual Funds Clearly Tell Us That There is a Bubble in the Stock Market(Vivek Kaul's Diary)

Jan 11, 2018

The maximum amount of money ever has come into equity mutual funds during the current financial year.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Nirvana denied: Has Value Failed?(The Honest Truth)

Jan 13, 2018

Should investors choose growth over value this year?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

CIPLA SHARE PRICE


Jan 23, 2018 03:34 PM

TRACK CIPLA

COMPARE CIPLA WITH

MARKET STATS